Autolus Therapeutics Ltd – (AUTL) Shares Bought by Partner Fund Management L.P.

Partner Fund Management L.P. increased its position in Autolus Therapeutics Ltd – (NASDAQ:AUTL) by 11.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 219,628 shares of the company’s stock after purchasing an additional 21,754 shares during the quarter. Partner Fund Management L.P.’s holdings in Autolus Therapeutics were worth $6,736,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of AUTL. Woodford Investment Management Ltd bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at about $42,643,000. Baker BROS. Advisors LP bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at about $6,304,000. Aquilo Capital Management LLC bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at about $4,018,000. Millennium Management LLC bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at about $3,910,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Autolus Therapeutics in the 2nd quarter valued at about $3,189,000. 44.20% of the stock is currently owned by institutional investors.

AUTL has been the topic of a number of research analyst reports. HC Wainwright initiated coverage on shares of Autolus Therapeutics in a report on Wednesday, October 24th. They issued a “buy” rating on the stock. Wells Fargo & Co reaffirmed a “buy” rating and issued a $50.00 target price (up from $38.00) on shares of Autolus Therapeutics in a report on Thursday, November 29th. Finally, Zacks Investment Research cut shares of Autolus Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $44.00.

Autolus Therapeutics stock opened at $39.50 on Thursday. Autolus Therapeutics Ltd – has a twelve month low of $19.17 and a twelve month high of $53.24.

WARNING: “Autolus Therapeutics Ltd – (AUTL) Shares Bought by Partner Fund Management L.P.” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/12/06/autolus-therapeutics-ltd-autl-shares-bought-by-partner-fund-management-l-p.html.

Autolus Therapeutics Profile

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Recommended Story: How to use beta for portfolio diversification

Want to see what other hedge funds are holding AUTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Autolus Therapeutics Ltd – (NASDAQ:AUTL).

Institutional Ownership by Quarter for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply